Bahto Biosciences
ActiveBahto Biosciences develops non-opioid small-molecule therapeutics for painful peripheral neuropathy, a condition with limited effective treatment options that afflicts more than 19 million Americans.
What it does
Bahto Biosciences is a health and lifetech company focused on developing non-opioid small-molecule therapeutics for painful peripheral neuropathy, a condition with limited effective treatment options. The company utilizes a proprietary chemical scaffold to generate novel composition-of-matter derivatives that have demonstrated in vivo efficacy. Bahto Biosciences aims to advance its lead candidate toward investigational new drug-enabling studies, potentially delivering the first disease-modifying therapy for this challenging condition. Founded by experienced drug discovery experts with a strong track record in advancing multiple drugs to clinical trials and successful asset development, Bahto Biosciences contributes to innovation by addressing unmet medical needs through pioneering therapeutic approaches.
Its site says now · captured 2026-08-26
Bahto Biosciences
Bahto Biosciences develops a non-opioid small-molecule therapeutic for painful peripheral neuropathy.
Next to it in Healthcare and bio · Non-opioid neuropathic pain therapeutics
- Adipo TherapeuticsPlug and Play PnP 2026
Adipo Therapeutic is a biotechnology company that is developing a novel asset for the treatment of obesity by increasing energy expenditure via mitochondria biogenesis and activation in white adipose tissue (fat browning).
- Cryton BiosciencesPlug and Play PnP 2026
Cryton Biosciences is developing a first-in-class dual-action drug that restores mitochondrial function in immune AND cancer cells resulting in tumor death.
- Diapin TherapeuticsPlug and Play PnP 2026
Novel Therapies for Cardiovascular and Metabolic Diseases
- RNARevivePlug and Play PnP 2026
RNARevive is developing a next-generation RNA platform that enables long-lasting, low-dose protein therapeutics. Our lead candidates tackle the anti-aging and longevity space, targeting osteoporosis, age-related macular degeneration (AMD), and liver diseases.
- FinalDoseY Combinator X26
Programmable DNA drug destroying all cancers, unlocking 80% of targets
- Scioto BiosciencesPlug and Play PnP 2025
Scioto is a preclinical stage company developing innovative therapies devoted to having a transformative impact.
- Eris BiotechY Combinator W24
Our drugs engage the immune system to fight tumors
- SynsoryBioY Combinator W24
"If-then" conditional logic for protein drugs